Casey Cosgrove, MD, a fellow at the Ohio State Comprehensive Cancer Center, discussed a pilot trial that screened patients with endometrial cancers for Lynch syndrome.The potential impact of this study could lead to the prevention of endometrial, ovarian, and colorectal cancers in the future, Cosgrove said.
Casey Cosgrove, MD, a fellow at the Ohio State Comprehensive Cancer Center, discussed a pilot trial that screened patients with endometrial cancers for Lynch syndrome.The potential impact of this study could lead to the prevention of endometrial, ovarian, and colorectal cancers in the future, Cosgrove said.
With over 60,000 cases of endometrial cancers occurring per year, screening has been recommended by several organizations. In this pilot study, Cosgrove completed testing on all endometrial patients at Ohio State by using immunohistochemistry and microsatellite stability testing.
If patients were found positive for Lynch syndrome, they then underwent germline testing to investigate whether or not the patient was born with the disease or not. Tumor testing was used to consolidate findings if the reason for mutations did not appear in the previous screenings.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More